AstraZeneca (AZN LN) announces positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in the lancet respiratory medicine
Importance
Level 1
#UNITED KINGDOM#EUROPE#ASTRAZENECA PLC#3I GROUP PLC#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#ASSET MANAGEMENT & CUSTODY BANKS#PHARMACEUTICALS (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#FTSE 100 INDEX#III#FTSE 100